Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is restructuring in order to leverage its peptide platform by prioritizing investment in its research and development pipeline programs and streamline its commercial operations.
 
The changes will refocus the company’s resources reducing expenses while investing in strategic development and commercialization partnerships of pipeline assets. As a part of the process, Dr. Adam Steensberg will replace Emmanuel Dulac as chief executive officer of Zealand as of March 30, 2022.
 
“The Board is focused on ensuring that the company continues to play to its strengths and believes that Dr. Adam Steensberg, its current executive vice president of Research & Development and chief medical officer, has the right skills set and experience having developed the company’s rich and deep pipeline under his tenure,” said Martin Nicklasson, chairman of the Board of Zealand Pharma. “I want to thank Emmanuel for his stewardship of the company over the last three years.”

Maximizing Value

Following a review of all business operations, Zealand plans to maximize the value of V-Go and Zegalogue through strategic partnerships and will restructure its commercial organization in the United States while ensuring continuity of services by maintaining patient, physician, and payor support for V-Go and Zegalogue.
 
Zealand will also seek commercial partnership opportunities for its late-stage clinical pipeline programs as it looks to further leverage its peptide platform though strategic collaborations. With the restructuring, the U.S. workforce will be reduced 90% by Q3 of this year with additional cost reductions implemented in Denmark.
 
“I realize that these changes impact employees in our organization and we are grateful to all our colleagues for their dedication and all they have done to improve the lives of patients,” said Adam Steensberg, president and chief executive officer of Zealand Pharma. “We have made the decision to restructure because we believe that seeking commercial partnerships will generate more value for the company and shareholders as we transform the company into a more focused and cost-effective organization.”
 
By improving its operational efficiency and targeting business development efforts, Zealand will be in position to fully leverage the value of its most advanced assets and develop new peptide-based therapies. It has a strong R&D pipeline with Phase III readouts this year for dasiglucagon in CHI and, glepaglutide in SBS in the second and third quarters respectively, and Phase I data for its Amylin analogue targeting obesity later this year.

Updated Financial Guidance

With the restructuring, the company is updating its financial guidance for 2022.
 
Net operating expenses in 2022 are now expected to be DKK 1,000 million +/-10%. This is a decrease of DKK 200 million from the prior guidance issued on March 10, 2022, and due to the change in commercial strategy, net product revenue from the sales of commercial products is now expected to be DKK 115 million +/- 10%. This is a decrease of DKK 125 million from the prior guidance and does not include any revenue from existing license agreements or from any potential partnerships. If such partnerships occur, Zealand will update the financial guidance accordingly.